RG002C0106
Phase 2Small molecule
RG002C0106 is one of 34 small molecule programs targeting IgA Nephropathy. It is currently in Phase 2.
1
Indications
3
Total Trials
3
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
99 competitors in Iga Nephropathy
#DrugCompanyPhaseTrials
1Avapro
SanofiPhase 3
Kerendia
BayerPhase 3
Farxiga
AstraZenecaPhase 3
Filspari
TTravere Therapeutics, Inc.
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
LNP023
NovartisPhase 3
Medrol
PfizerPhase 2
Vanrafia
NovartisPhase 2
Telitacicept
VVor Biopharma
Phase 3
Mezagitamab
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
IgA Nephropathy1 trial
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
Recruiting·RRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.·Phase 2·NCT07305974·30 enrolled
Phase 11 trial
A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults
Active, not recruiting·RRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.·Phase 1·NCT06494527·30 enrolled
Renal Impairment1 trial
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
Not yet recruiting·RRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.·Phase 1·NCT07445906·24 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RG002C0106. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details